These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17146985)

  • 1. Duffy-Santner confidence intervals for the two-stage three-outcome design.
    Furth AF; Sargent DJ
    J Biopharm Stat; 2006; 16(6):875-80. PubMed ID: 17146985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corrected profile likelihood confidence interval for binomial paired incomplete data.
    Pradhan V; Menon S; Das U
    Pharm Stat; 2013; 12(1):48-58. PubMed ID: 23296487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Confidence intervals for the binomial parameter: some new considerations.
    Reiczigel J
    Stat Med; 2003 Feb; 22(4):611-21. PubMed ID: 12590417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Covariate-adjusted response-adaptive designs for binary response.
    Rosenberger WF; Vidyashankar AN; Agarwal DK
    J Biopharm Stat; 2001 Nov; 11(4):227-36. PubMed ID: 12018777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimators and confidence intervals for the proportion using binary auxiliary information with applications to pharmaceutical studies.
    Rueda M; Muñoz JF; Arcos A; Álvarez E; Martínez S
    J Biopharm Stat; 2011 May; 21(3):526-54. PubMed ID: 21442524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated confidence intervals for adaptive group sequential trials.
    Mehta CR; Bauer P; Posch M; Brannath W
    Stat Med; 2007 Dec; 26(30):5422-33. PubMed ID: 17918195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interval estimation in two-stage, drop-the-losers clinical trials with flexible treatment selection.
    Neal D; Casella G; Yang MC; Wu SS
    Stat Med; 2011 Oct; 30(23):2804-14. PubMed ID: 21823142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint.
    Healy BC; Ikle D; Macklin EA; Cutter G
    Mult Scler; 2010 Jul; 16(7):840-7. PubMed ID: 20530124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two confidence interval approaches on the dependability coefficient in a two-factor crossed design.
    Ting N; Cappelleri JC; Bushmakin AG
    J Biopharm Stat; 2009 Jul; 19(4):610-24. PubMed ID: 20183429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An asymptomatic confidence interval for the response at the stationary point of a quadratic response surface.
    Chinchilli VM; Carter WH; Breen TJ; Campbell ED
    J Biopharm Stat; 1991; 1(2):287-301. PubMed ID: 1844701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flexible design of two-stage adaptive procedures for phase III clinical trials.
    Koyama T
    Contemp Clin Trials; 2007 Jul; 28(4):500-13. PubMed ID: 17307399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative methods to evaluate trial level surrogacy.
    Abrahantes JC; Shkedy Z; Molenberghs G
    Clin Trials; 2008; 5(3):194-208. PubMed ID: 18559408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing phase II studies in cancer with time-to-event endpoints.
    Owzar K; Jung SH
    Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and analysis of crossover trials for absorbing binary endpoints.
    Nason M; Follmann D
    Biometrics; 2010 Sep; 66(3):958-65. PubMed ID: 19930189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confidence intervals for confirmatory adaptive two-stage designs with treatment selection.
    Bebu I; Dragalin V; Luta G
    Biom J; 2013 May; 55(3):294-309. PubMed ID: 23553644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the estimation of the binomial probability in multistage clinical trials.
    Jung SH; Kim KM
    Stat Med; 2004 Mar; 23(6):881-96. PubMed ID: 15027078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confidence intervals and p-values for Williams' and other step-down multiple comparison tests against control.
    Channon EJ; McEntegart DJ
    J Biopharm Stat; 2001; 11(1-2):45-63. PubMed ID: 11459442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of methods for the construction of confidence interval for relative risk in stratified matched-pair designs.
    Tang NS; Li HQ; Tang ML
    Stat Med; 2010 Jan; 29(1):46-62. PubMed ID: 19856277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonparametric confidence intervals for Tmax in sequence-stratified crossover studies.
    Willavize SA; Morgenthien EA
    Pharm Stat; 2008; 7(1):9-19. PubMed ID: 17256803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.